Knowledge and diversity the watchwords for Roche's early research
This article was originally published in Scrip
Executive Summary
The well-documented decline in Big Pharma's R&D productivity, in parallel with ever-escalating costs, has spurred the re-engineering of processes at many firms over the past few years. For Roche, ways of moving away from the old "attrition-based" model include the early adoption of new techniques to understand precise disease mechanisms and the pursuit of partnerships.